Enrollment Headaches Cause NMT To Drop Migraine Trial
This article was originally published in The Gray Sheet
Executive Summary
NMT Medical is halting its chase of a migraine indication for its patent foramen ovale closure device after an earlier trial missed its primary endpoint and a second, larger trial has suffered enrollment problems
You may also be interested in...
SeptRx Launches PFO Device Trial, Eyeing Mid-2012 CE-Mark Submission
Controversy remains over the clinical benefit of using a patent foramen ovale closure device to prevent strokes or other neurological events, but that has not stopped California startup SeptRx from moving ahead with early stage development of its offering.
SeptRx Launches PFO Device Trial, Eyeing Mid-2012 CE-Mark Submission
Controversy remains over the clinical benefit of using a patent foramen ovale closure device to prevent strokes or other neurological events, but that has not stopped California startup SeptRx from moving ahead with early stage development of its offering.
Will Positive PFO Closure Trials For Stroke Help Or Hurt Other Indications?
As pivotal trials for patent foramen ovale (PFO) closure devices to treat stroke start wrapping up, cardiologists are questioning what impact the trial results will have on studies for other indications